SLC5A2 and cardiovascular disorder: Several large clinical trials reported that SGLT2 inhibitors such as empagliflozin, canagliflozin, and dapagliflozin reduced the incidence of end-stage kidney disease, doubling of the serum creatinine levels from baseline, or death from renal or cardiovascular disease [5–7].